Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.

Endt, Kathrin; Goepfert, Jens; Omlin, Aurelius Gabriel; Athanasiou, Alcibiade; Tennstedt, Pierre; Guenther, Anna; Rainisio, Maurizio; Engeler, Daniel S; Steuber, Thomas; Gillessen, Silke; Joos, Thomas; Schiess, Ralph (2017). Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE, 12(8), e0181557. Public Library of Science 10.1371/journal.pone.0181557

[img]
Preview
Text
Unbenannt3.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Prostate Cancer (PCa) diagnosis is currently hampered by the high false-positive rate of PSA evaluations, which consequently may lead to overtreatment. Non-invasive methods with increased specificity and sensitivity are needed to improve diagnosis of significant PCa. We developed and technically validated four individual immunoassays for cathepsin D (CTSD), intercellular adhesion molecule 1 (ICAM1), olfactomedin 4 (OLFM4), and thrombospondin 1 (THBS1). These glycoproteins, previously identified by mass spectrometry using a Pten mouse model, were measured in clinical serum samples for testing the capability of discriminating PCa positive and negative samples. The development yielded 4 individual immunoassays with inter and intra-variability (CV) <15% and linearity on dilution of the analytes. In serum, ex vivo protein stability (<15% loss of analyte) was achieved for a duration of at least 24 hours at room temperature and 2 days at 4°C. The measurement of 359 serum samples from PCa positive (n = 167) and negative (n = 192) patients with elevated PSA (2-10 ng/ml) revealed a significantly improved accuracy (P <0.001) when two of the glycoproteins (CTSD and THBS1) were combined with %fPSA and age (AUC = 0.8109; P <0.0001; 95% CI = 0.7673-0.8545). Conclusively, the use of CTSD and THBS1 together with commonly used parameters for PCa diagnosis such as %fPSA and age has the potential to improve the diagnosis of PCa.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Omlin, Aurelius Gabriel

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1932-6203

Publisher:

Public Library of Science

Language:

English

Submitter:

Nicole Corminboeuf

Date Deposited:

12 Feb 2018 16:35

Last Modified:

25 Oct 2019 12:29

Publisher DOI:

10.1371/journal.pone.0181557

PubMed ID:

28767721

BORIS DOI:

10.7892/boris.111230

URI:

https://boris.unibe.ch/id/eprint/111230

Actions (login required)

Edit item Edit item
Provide Feedback